{"nctId":"NCT03143218","briefTitle":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)","startDateStruct":{"date":"2017-04-17","type":"ACTUAL"},"conditions":["Malaria,Falciparum","Children, Only"],"count":5920,"armGroups":[{"label":"SMC with SP+AQ","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RABIPUR®","Drug: SMC with SP+AQ"]},{"label":"RTS,S/AS01","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RTS,S/AS01","Drug: SMC placebo"]},{"label":"RTS,S/AS01 PLUS SMC with SP+AQ","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RTS,S/AS01","Drug: SMC with SP+AQ"]}],"interventions":[{"name":"RABIPUR®","otherNames":[]},{"name":"RTS,S/AS01","otherNames":[]},{"name":"SMC with SP+AQ","otherNames":[]},{"name":"SMC placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial\n* The child is 5 - 17 months of age at the time of first vaccination\n* A parent or legally recognised guardian provides informed consent for the child to join the trial\n\nExclusion Criteria:\n\n* The child is a transient resident in the study area\n* The child is in care\n* The age of the child is outside the stipulated range\n* The child has a history of an adverse reaction to SP or AQ\n* The child has a serious underlying illness, including known HIV infection, unless this is well controlled by treatment, or severe malnutrition (weight for age or mid arm circumference Z scores \\< 3 SD)\n* The child is known to have an immune deficiency disease or is receiving an immunosuppressive drug\n* The child has previously received a malaria vaccine.\n* The child is enrolled in another malaria intervention trial\n* The parents or guardians do not provide informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Months","maximumAge":"17 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Clinical Episodes of Malaria","description":"Passive surveillance to detect episode of fever (temperature \\> 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"304.8","spread":null},{"groupId":"OG001","value":"278.2","spread":null},{"groupId":"OG002","value":"113.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Episodes of Uncomplicated Febrile Illness","description":"Passive and active surveillance to detect cases with temperature \\> 37.5o C), or a history of fever within the past 48 hours, with a positive blood film (any level of asexual parasitaemia) or a positive rapid diagnostic test (RDT) for malaria","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Hospital Admissions With Malaria, Including Severe Malaria","description":"Hospital admissions with malaria, including cases of severe malaria which meet WHO criteria for a diagnosis of severe malaria.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Prevalence of Malaria Infection Not Severe Enough to Warrant a Clinic Visit","description":"Active surveillance of malaria at household level to assess the prevalence of malaria infection not severe enough to warrant a clinic visit detected in a subset of randomly selected children.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Prevalence of Malaria Parasitaemia, Including Gametocytaemia and the Prevalence of Moderate and Severe Anemia and Malnutrition","description":"The prevalence of malaria parasitaemia, including gametocytaemia, moderate and severe anaemia and malnutrition at the end of the malaria transmission season","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs), including any deaths, occurring at any time during the study with special reference to any cases of meningitis and cerebral malaria (WHO case definition)","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Immune Response to the Vaccine (Anti-CSP Antibody Concentrations)","description":"After priming and after each booster dose, determined in a sub-sample of children","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Drug Resistance to SP and AQ","description":"The presence of molecular markers of resistance to SP and AQ in parasite positive samples","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Prevalence of Malaria Parasitaemia in School Aged Children","description":"The prevalence of malaria parasitaemia at the end of the malaria transmission season in school-age children resident in the study areas, to determine overall malaria transmission","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"SP+AQ Drug Sensitivity","description":"The 28-day treatment outcome in children with asymptomatic malaria parasitaemia treated with SP+AQ.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Acceptability of RTS,S and SMC","description":"The acceptability of the two interventions (separately and combined) to the health care deliverers and to the study communities (standardized questionnaires)","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Feasibility of Introducing Two Malaria Control Strategies Simultaneously","description":"The feasibility of introducing two malaria control strategies simultaneously from the health system perspective (structured observations and interviews with health system officials)","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":97,"n":1965},"commonTop":[]}}}